Valerio Therapeutics SA
SWB:C4X

Watchlist Manager
Valerio Therapeutics SA Logo
Valerio Therapeutics SA
SWB:C4X
Watchlist
Price: 0.054 EUR Market Closed
Market Cap: 27.8m EUR

Net Margin
Valerio Therapeutics SA

-721.8%
Current
-1 047%
Average
-6.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-721.8%
=
Net Income
-13.2m
/
Revenue
1.8m

Net Margin Across Competitors

No Stocks Found

Valerio Therapeutics SA
Glance View

Market Cap
27.8m EUR
Industry
Biotechnology

Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. The company is headquartered in Paris, Ile-De-France and currently employs 25 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

C4X Intrinsic Value
0.032 EUR
Overvaluation 41%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-721.8%
=
Net Income
-13.2m
/
Revenue
1.8m
What is the Net Margin of Valerio Therapeutics SA?

Based on Valerio Therapeutics SA's most recent financial statements, the company has Net Margin of -721.8%.

Back to Top